FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2295977529> ?p ?o ?g. }

• W2295977529 endingPage "A68" @default.
• W2295977529 startingPage "A68.1" @default.
• W2295977529 abstract "<h3>Introduction</h3> Treatment candidates for emerging small molecule therapy in hepatitis C virus (HCV) have yet to be defined. Treatment naive patients who have opted to delay standard of care therapy will compete with treatment failures for these novel agents. For this reason, disease progression needs to be clearly defined. While the role of liver biopsy in the management of HCV remains contentious, data on the progression of fibrosis can only be ascertained from sequential liver biopsy. Thus, patients in our unit who underwent interval biopsies were studied to identify the factors which determine disease progression. <h3>Methods</h3> A total of 242 mono-infected HCV patients underwent a repeat liver biopsy. Patients who declined treatment and opted for a strategy of watchful waiting and those who failed combination antiviral therapy were offered an interval biopsy. Demographic data, viral parameters, ALT level, necro-inflammatory (NI) score and the presence of co-factors were collated to investigate their impact on progression of disease. Statistical analysis was performed using a Linear Mixed Model with SPSS 16 and the level of significance used was 5%. <h3>Results</h3> 121/242 patients had evidence of disease progression on interval biopsy. The median interval between biopsies was 50 months (range 11–133). Age, ALT level and necro-inflammatory score were all predictors of progressive fibrosis, p<0.002, p<0.001, p<0.0001, respectively. The presence of a co-factor, defined as features of concurrent alcohol ingestion, steatosis or iron on liver biopsy lead to a doubling of the rate of fibrosis when compared with no co-factor. Neither genotype nor gender had a significant impact on fibrosis progression. <h3>Conclusion</h3> Liver biopsy benchmarks the extent of fibrosis in chronic HCV infection. This is critical in determining treatment response; moreover it provides an insight into future disease progression in those who decline treatment. This study demonstrates age. ALT and NI score as factors associated with accelerated disease, while the presence of a co-factor can have a synergistic effect, doubling the rate of fibrosis progression in HCV infection." @default.
• W2295977529 created "2016-06-24" @default.
• W2295977529 creator A5023606749 @default.
• W2295977529 creator A5032498181 @default.
• W2295977529 creator A5047789971 @default.
• W2295977529 creator A5050295216 @default.
• W2295977529 creator A5050807039 @default.
• W2295977529 creator A5053096526 @default.
• W2295977529 creator A5061814401 @default.
• W2295977529 creator A5085622820 @default.
• W2295977529 date "2010-04-01" @default.
• W2295977529 modified "2023-09-26" @default.
• W2295977529 title "PTU-049 Rate of disease progression and the influence of co-factors in hepatitis C virus as determined by interval liver biopsy" @default.
• W2295977529 doi "https://doi.org/10.1136/gut.2009.209056i" @default.
• W2295977529 hasPublicationYear "2010" @default.
• W2295977529 type Work @default.
• W2295977529 sameAs 2295977529 @default.
• W2295977529 citedByCount "0" @default.
• W2295977529 crossrefType "journal-article" @default.
• W2295977529 hasAuthorship W2295977529A5023606749 @default.
• W2295977529 hasAuthorship W2295977529A5032498181 @default.
• W2295977529 hasAuthorship W2295977529A5047789971 @default.
• W2295977529 hasAuthorship W2295977529A5050295216 @default.
• W2295977529 hasAuthorship W2295977529A5050807039 @default.
• W2295977529 hasAuthorship W2295977529A5053096526 @default.
• W2295977529 hasAuthorship W2295977529A5061814401 @default.
• W2295977529 hasAuthorship W2295977529A5085622820 @default.
• W2295977529 hasConcept C126322002 @default.
• W2295977529 hasConcept C203014093 @default.
• W2295977529 hasConcept C2522874641 @default.
• W2295977529 hasConcept C2775934546 @default.
• W2295977529 hasConcept C2776175330 @default.
• W2295977529 hasConcept C2776408679 @default.
• W2295977529 hasConcept C2776455275 @default.
• W2295977529 hasConcept C2777766500 @default.
• W2295977529 hasConcept C2780559512 @default.
• W2295977529 hasConcept C71924100 @default.
• W2295977529 hasConcept C90924648 @default.
• W2295977529 hasConceptScore W2295977529C126322002 @default.
• W2295977529 hasConceptScore W2295977529C203014093 @default.
• W2295977529 hasConceptScore W2295977529C2522874641 @default.
• W2295977529 hasConceptScore W2295977529C2775934546 @default.
• W2295977529 hasConceptScore W2295977529C2776175330 @default.
• W2295977529 hasConceptScore W2295977529C2776408679 @default.
• W2295977529 hasConceptScore W2295977529C2776455275 @default.
• W2295977529 hasConceptScore W2295977529C2777766500 @default.
• W2295977529 hasConceptScore W2295977529C2780559512 @default.
• W2295977529 hasConceptScore W2295977529C71924100 @default.
• W2295977529 hasConceptScore W2295977529C90924648 @default.
• W2295977529 hasIssue "Suppl 1" @default.
• W2295977529 hasLocation W22959775291 @default.
• W2295977529 hasOpenAccess W2295977529 @default.
• W2295977529 hasPrimaryLocation W22959775291 @default.
• W2295977529 hasRelatedWork W1984228095 @default.
• W2295977529 hasRelatedWork W2042555983 @default.
• W2295977529 hasRelatedWork W2054144404 @default.
• W2295977529 hasRelatedWork W2070486530 @default.
• W2295977529 hasRelatedWork W2086939368 @default.
• W2295977529 hasRelatedWork W2115423135 @default.
• W2295977529 hasRelatedWork W2156120764 @default.
• W2295977529 hasRelatedWork W2398671908 @default.
• W2295977529 hasRelatedWork W2945890717 @default.
• W2295977529 hasRelatedWork W4318480679 @default.
• W2295977529 hasVolume "59" @default.
• W2295977529 isParatext "false" @default.
• W2295977529 isRetracted "false" @default.
• W2295977529 magId "2295977529" @default.
• W2295977529 workType "article" @default.